Tailored Antiplatelet Therapy Following PCI

Mayo Clinic5,276 enrolled

Overview

Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some studies have suggested that patients who have a certain genetic liver enzyme abnormality (known as cytochrome P450 2C19 \[CYP2C19\] \*2 or \*3 allele) may have a reduced ability to activate clopidogrel, and therefore may have a lowered response to clopidogrel. It is thought that perhaps people who have a coronary stent procedure may have this genetic liver enzyme abnormality. There is a research genetic test available to determine whether or not someone has this genetic liver enzyme abnormality. Ticagrelor, is a newer anti-platelet drug that is not dependent on the CYP2C19 liver enzyme for its activation and hence in poor clopidogrel metabolizers, alternative drugs like Ticagrelor have been recommended for use as an anti-platelet agent after PCI. The purpose of this study is to determine if genetic testing can identify the best anti-platelet therapy, for patients who undergo a coronary stent placement and do not activate clopidogrel very well.

TAILOR-PCI is a multi-site, open label, prospective, randomized trial testing the hypothesis that after percutaneous coronary intervention (PCI), using a genotyping strategy ticagrelor 90 mg twice per day is superior to clopidogrel 75 mg per day in reducing a composite endpoint of major adverse cardiovascular events (MACE), i.e., non-fatal myocardial infarction, non-fatal stroke, severe recurrent ischemia, cardiovascular (CV) death, and stent thrombosis (primary endpoints) in CYP2C19 reduced function allele patients. Patients who undergo PCI will be randomized to a conventional therapy arm (i.e., to receive clopidogrel 75 mg once daily without prospective genotyping guidance) versus a prospective CYP2C19 genotype-based anti-platelet therapy approach (ticagrelor 90 mg bid in CYP2C19 \*2 or \*3 reduced function allele patients, clopidogrel 75 mg once daily in non-\*2 or -\*3 CYP2C19 patients). Buccal swabs will be obtained for those subjects randomized to the prospective genotyping arm. All subjects will have a blood sample drawn for DNA analysis but genotyping using these DNA samples will be performed only after completion of the duration of anti-platelet therapy (i.e., after one year). The primary endpoints will be assessed prospectively and will be compared between the conventional arm and the prospective genotyping arm among those identified as reduced function CYP2C19 allele carriers according to the 1-year genotype results.

Study Type

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion * Patient \>18 years of age * Patient presents with acute coronary syndrome (ACS) or stable coronary artery disease (CAD) * Patient is eligible for PCI * Patient is willing and able to provide informed written consent 5.3 Exclusion * Patient not able to receive 12 months of dual anti-platelet therapy * Failure of index PCI * Patient or physician refusal to enroll in the study * Patient with known CYP2C19 genotype prior to randomization * Planned revascularization of any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure * Anticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up period, example for elective surgery * Serum creatinine \>2.5 mg/dL within 7 days of index procedure * Platelet count \<80,000 or \>700,000 cells/mm3, or white blood cell count \<3,000 cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index procedure. * History of intracranial hemorrhage * Known hypersensitivity to clopidogrel or ticagrelor or any of its components * Patient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint * Patient previously enrolled in this study * Patient is pregnant, lactating, or planning to become pregnant within 12 months * Patient has received an organ transplant or is on a waiting list for an organ transplant * Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the procedure * Patient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous, etc.) * Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor) * Concomitant use of simvastatin/lovastatin \> 40 mg qd * Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine) * Non-cardiac condition limiting life expectancy to less than one year, per physician judgment (e.g. cancer) * Known history of severe hepatic impairment * Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions * Patient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding * Inability to take aspirin at a dosage of 100 mg or less * Current substance abuse (e.g., alcohol, cocaine, heroin, etc.)

Locations (41)

Mayo Clinic in Arizona

Scottsdale, Arizona, United States

Sharp HealthCare

San Diego, California, United States

Zuckerberg San Francisco General

San Francisco, California, United States

Mayo Clinic in Florida

Jacksonville, Florida, United States

NCH Heart Institute

Naples, Florida, United States

Outcomes

Primary Outcomes

Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.

Number of subjects who experienced major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis in subjects identified as CPY2C19 LOF carriers by TaqMan.

Time frame: 1 year after percutaneous coronary intervention (PCI)

Occurrence of the a Major Adverse Cardiovascular Event

Number of subjects to experience a major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis.

Time frame: Approximately 3 years after percutaneous coronary intervention (PCI)

Secondary Outcomes

Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.

Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding in subjects identified as CYP2C19 LOF carriers by TaqMan

Time frame: 1 year after percutaneous coronary intervention (PCI)

Thrombolysis in Myocardial Infarction Major or Minor Bleeding

Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding